

CURRICULUM VITAE

PERSONAL INFORMATION

Name **VERLENGIA GIANLUCA**

WORK EXPERIENCE

- Dates (from – to) **01/04/2016-TODAY**
 - Name and address of employer Michele Simonato, University Vita-Salute San Raffaele, Milano, Italy
 - Type of business or sector Research
 - Occupation or position held Post Doc
 - Main activities and responsibilities Engineering of Herpes Simplex Virus 1-based vectors for gene therapy approaches in animal models of temporal lobe epilepsy

- Dates (from – to) **01/01/2013-01/04/2016**
 - Name and address of employer Michele Simonato, University of Ferrara, Ferrara, Italy
 - Type of business or sector Research
 - Occupation or position held Post Doc
 - Main activities and responsibilities Construction and characterization of Herpes Simplex Virus 1-based vectors for gene delivery to the central nervous system

- Dates (from – to) **01/10/2011-30/11/2012**
 - Name and address of employer Joseph C. Glorioso, University of Pittsburgh, Pittsburgh (PA), USA
 - Type of business or sector Research
 - Occupation or position held Visiting PhD student
 - Main activities and responsibilities Construction and characterization of viral vectors based on Herpes Simplex Virus-1.

- Dates (from – to) **01/06/2010-31/08/2010**
 - Name and address of employer Joseph C. Glorioso, University of Pittsburgh, Pittsburgh (PA), USA
 - Type of business or sector Research
 - Occupation or position held Visiting PhD student
 - Main activities and responsibilities Induced pluripotent stem cells generation and maintenance in culture

- Dates (from – to) **01/01/2010-31/12/2012**
- Name and address of employer Michele Simonato, University of Ferrara, Ferrara, Italy
 - Type of business or sector Research
 - Occupation or position held PhD student
- Main activities and responsibilities In vivo and in vitro studies on experimental models of epilepsy

- Dates (from – to) **01/04/2009-31/12/2009**
- Name and address of employer Michele Simonato, University of Ferrara, Ferrara, Italy
 - Type of business or sector Research
 - Occupation or position held Research fellow
- Main activities and responsibilities Preclinical study in a drug development project in collaboration with pharmaceutical industry

- Dates (from – to) **01/03/2008-31/08/2008**
- Name and address of employer Michelangelo Campanella, Rosella Abeti, University College London, London, UK
 - Type of business or sector Research
 - Occupation or position held Stage
- Main activities and responsibilities Laboratory research-based stage for Master's research thesis dissertation

- Dates (from – to) **01/04/2005-04/10/2005**
- Name and address of employer Mirko Pinotti, Francesco Bernardi, University of Ferrara, Ferrara, Italy
 - Type of business or sector Research
 - Occupation or position held Stage
- Main activities and responsibilities Laboratory research-based stage for Bachelor's research thesis dissertation

EDUCATION AND TRAINING

- Dates (from – to) 09/2005-09/2008
- Name and type of organization providing education and training University of Ferrara
 - Title of qualification awarded Master Degree in medical and pharmaceutical biotechnology

- Dates (from – to) 09/2002-09/2005
- Name and type of organization providing education and training University of Ferrara
 - Title of qualification awarded Bachelor Degree in biotechnology

TEACHING

- Dates (from – to) 2017-2020
 - Class title Principles of Pharmacology, Tutorial class activity
 - Program International Medical Doctor Program, University Vita-Salute San Raffaele
- Dates (from – to) 2019-2020
 - Class title General and preclinical toxicology, the use of animal models in biomedical research
 - Program Master Degree in Biotechnology and Medical Biology, University Vita-Salute San Raffaele
- Dates 2019
 - Class title Terapia genica: quadro normativo regolatorio europeo e nazionale
 - Program Aspetti Regolatori, Brevettuali ed Economici dello Sviluppo dei Farmaci e dei dispositivi medici, University of Ferrara

PEER-REVIEWED PUBLICATIONS

- **Parkinson's disease recovery by GM1 oligosaccharide treatment in the B4galnt1 +/- mouse model**
Chiricozzi E, Mauri L, Lunghi G, Di Biase E, Fazzari M, Maggioni M, Valsecchi M, Prioni S, Loberto N, Pomè DY, Ciampa MG, Fato P, Verlengia G, Cattaneo S, Assini R, Wu G, Alselehdar S, Ledeen RW, Sonnino S.
Sci Rep 2019 Dec 18;9(1):19330. doi: 10.1038/s41598-019-55885-2.
- **Cellular Antisilencing Elements Support Transgene Expression from Herpes Simplex Virus Vectors in the Absence of Immediate Early Gene Expression**
Han F, Miyagawa Y, Verlengia G, Ingusci S, Soukupova M, Simonato M, Glorioso JC, Cohen JB.
J Virol. 2018 Aug 16;92(17). pii: e00536-18. doi: 10.1128/JVI.00536-18. Print 2018 Sep 1.
- **New Tools for Epilepsy Therapy**
Falcicchia C, Simonato M, Verlengia G.
Front Cell Neurosci. 2018 May 29;12:147. doi: 10.3389/fncel.2018.00147. eCollection 2018. Review.
- **Personalized Needles for Microinjections in the Rodent Brain**
Paolone G, Falcicchia C, Verlengia G, Barbieri M, Binaschi A, Pallotto F, Paradiso B, Soukupova M, Zucchini S, Simonato M.
J Vis Exp. 2018 Jan 24;(131). doi: 10.3791/55751.
- **Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes**
Miyagawa Y, Verlengia G, Reinhart B, Han F, Uchida H, Zucchini S, Goins WF, Simonato M, Cohen JB, Glorioso JC.
Mol Ther Methods Clin Dev. 2017 Jun 16;6:79-90. doi: 10.1016/j.omtm.2017.06.001. eCollection 2017 Sep 15.
- **Engineered HSV vector achieves safe long-term transgene expression in the central nervous system**
Verlengia G, Miyagawa Y, Ingusci S, Cohen JB, Simonato M, Glorioso JC.
Sci Rep. 2017 May 4;7(1):1507. doi: 10.1038/s41598-017-01635-1.
- **Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity.**
Miyagawa Y, Marino P, Verlengia G, Uchida H, Goins WF, Yokota S, Geller DA, Yoshida O, Mester J, Cohen JB, Glorioso JC.
Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):E1632-41. doi: 10.1073/pnas.1423556112. Epub 2015 Mar 16.
- **Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy.**
Cifelli P, Palma E, Roseti C, Verlengia G, Simonato M.
Front Cell Neurosci. 2013 Jul 11;7:108. doi: 10.3389/fncel.2013.00108. eCollection 2013.
- **Bradykinin B₂ receptors increase hippocampal excitability and susceptibility to seizures in mice.**
Rodi D, Buzzi A, Barbieri M, Zucchini S, Verlengia G, Binaschi A, Regoli D, Boschi A, Ongali B, Couture R, Simonato M.
Neuroscience. 2013 Sep 17;248:392-402. doi: 10.1016/j.neuroscience.2013.06.038. Epub 2013 Jun 27.
- **Increased excitability in tat-transgenic mice: role of tat in HIV-related neurological disorders.**
Zucchini S, Pittaluga A, Brocca-Cofano E, Summa M, Fabris M, De Michele R, Bonaccorsi A, Busatto G, Barbanti-Brodano G, Altavilla G, Verlengia G, Cifelli P, Corallini A, Caputo A, Simonato M.
Neurobiol Dis. 2013 Jul;55:110-9. doi: 10.1016/j.nbd.2013.02.004. Epub 2013 Feb 27.